Skip to main content

Table 1 Clinicopathological characteristics of metastatic advanced melanoma patients from the RECI1 cohort (N = 112)

From: SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

Characteristics

N (%)

Age yr, median (range)

57 (25-80)

Gender

 Male

55 (49.1)

 Female

57 (50.9)

BRAF status

 mut

59 (52.7)

 wt

53 (47.3)

SEMA6A

 Low

76 (67,9)

 High

36 (32,1)

Metastatic Site

 Lymph Node

55 (49.1)

 Cutaneous/subcutaneous

30 (26.8)

 Lung

14 (12.5)

 Brain

6 (5.4)

 Liver

3 (2.7)

 Other

4 (3.6)